GABA A receptor alpha-1/beta-1/gamma-2 · PROTEIN COMPLEX · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13GABA A receptor alpha-1/beta-1/gamma-2 shows approved-linked disease relevance led by insomnia. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P14867. Start with insomnia, then reuse UniProt P14867 as the stable protein anchor across project notes and exports.
Start with insomnia, then reuse UniProt P14867 as the stable protein anchor across project notes and exports.
GABA A receptor alpha-1/beta-1/gamma-2 shows approved-linked disease relevance led by insomnia. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with insomnia because it currently carries approved-linked support. Linked drugs include ZALEPLON, ZOLPIDEM TARTRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyGamma-aminobutyric acid receptor subunit alpha-1
Review this target as GABA A receptor alpha-1/beta-1/gamma-2, mapped to UniProt P14867. ChEMBL maps the protein component as Gamma-aminobutyric acid receptor subunit alpha-1. Sequence length is 456 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats GABA A receptor alpha-1/beta-1/gamma-2 as ChEMBL target CHEMBL2111392, mapped to UniProt P14867. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether GABA A receptor alpha-1/beta-1/gamma-2 is the right protein anchor across sources, using UniProt P14867 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why insomnia is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | GABA A receptor alpha-1/beta-1/gamma-2 |
| Target Type | PROTEIN COMPLEX |
| Organism | Homo sapiens |
| UniProt | P14867 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Gamma-aminobutyric acid receptor subunit alpha-1 |
| UniProt Accession | P14867 |
| Component Type | Protein |
| Sequence Length | 456 aa |
Gamma-aminobutyric acid receptor subunit alpha-1
Review this target as GABA A receptor alpha-1/beta-1/gamma-2, mapped to UniProt P14867. ChEMBL maps the protein component as Gamma-aminobutyric acid receptor subunit alpha-1. Sequence length is 456 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
GABA A receptor alpha-1/beta-1/gamma-2 shows approved-linked disease relevance led by insomnia. 5 more disease programs remain visible in the same review block.
Start review with insomnia because it currently carries approved-linked support. Linked drugs include ZALEPLON, ZOLPIDEM TARTRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL381059 | 9.57 | Ki | 0.27 | Preclinical |
| CHEMBL206071 | 8.39 | Ki | 4.1 | Preclinical |
| CHEMBL12 | 7.92 | Ki | 12.0 | Approved |
| CHEMBL205257 | 7.85 | Ki | 14.0 | Preclinical |
| CHEMBL229534 | 7.47 | EC50 | 34.0 | Preclinical |
| CHEMBL1890408 | 7.4 | IC50 | 40.0 | Preclinical |
| CHEMBL911 | 7.28 | Ki | 53.0 | Approved |
| CHEMBL15891 | 7.17 | IC50 | 67.0 | Approved |
| CHEMBL32991 | 6.5 | EC50 | 320.0 | Preclinical |
| CHEMBL5086854 | 5.82 | IC50 | 1500.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 10 | 8 | 7.6 |
| protein complex format | 2 | 3 | 6.7 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 9 | 7 | 4.6 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 4 | 3 | 4.7 |